• Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • News Feed
    • Get The Study
    Prostate Cancer Free
    • Prostate Cancer
      • Prostate Cancer
      • Risk Factors
      • Symptoms
      • The Prostate
      • Tests and Diagnosis
      • PSA
      • Gleason Score
      • Stages
      • Risk Groups
    • Patients
      • Patient Advice
      • Patient Worksheet
      • Diet & Lifestyle
      • Glossary & Terms
      • Prostate Cancer News
      • Videos
    • Treatments
      • Treatment Options
      • Compare Treatments
      • – Low Risk
      • – Intermediate Risk
      • – High Risk
      • Side Effects
      • Successful Treatments
      • Get The Study
    • The Foundation
      • About Us
        • Terms of Use
        • Privacy Policy
      • Study Group
      • Internship Opportunities
      • Sponsors & Donors
      • Donate
        • Donate while Shopping at Amazon
    • Get The Study
    Select Page

    PCa Commentary #131: ENZALUTAMIDE (‘XTANDI’): AN UPDATE — The Many Faces of Enzalutamide

    by Dr. Ed Weber | Feb 7, 2019 | PCa Commentary

    Enzalutamide (ENZ) was reviewed in the PCa Commentary of March/April 2014. Many important developments have taken place since then. This Commentary will discuss the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address...

    PCa Commentary #130: Ga68-PSMA-11 PET/CT Scanning at Initial Diagnosis for High-Risk Prostate Cancer: What is missed by conventional staging and does it matter.

    by Dr. Ed Weber | Feb 6, 2019 | PCa Commentary

    This Commentary benefitted from a review and suggestions from Thomas Hope, MD, Associate Professor of Abdominal Imaging and Nuclear Medicine, UCSF THE FIRST QUESTION likely, is why present a Commentary about the Gallium68-PSMA-11 PET/CT scan.  Its...

    PCa Commentary: #129 THE AXUMIN PET/CT SCAN: ITS CLINICAL UTILITY — AN UPDATE

    by Dr. Ed Weber | Dec 6, 2018 | PCa Commentary

    It has been one year since the Commentary featured the Axumin PET/CT in the November 2017 issue [control+click link to follow].  A great deal of new research about this scan performance has been published since then. The material in this issue is based on this...

    PCa Commentary #128: IMMUNOTHERAPY FOR PROSTATE CANCER: Immune Checkpoint Inhibitors — The Search for Clues for Which Men Will Benefit and How Best to Treat Them.

    by Dr. Ed Weber | Nov 2, 2018 | PCa Commentary

    Harnessing our immune system to treat cancer has been an elusive goal for decades. Research in immunotherapy is intense with active study of the newest advances, i.e. checkpoint inhibitors and CAR T cell technology. Checkpoint inhibitors have yielded encouraging...

    PCa Commentary #127: DECIPHER AND A HYBRID CLINICAL – GENOMIC CLASSIFIER: Improving the Prognostic Accuracy of NCCN Risk Categories

    by Dr. Ed Weber | Oct 7, 2018 | PCa Commentary

    The conventional National Cooperative Cancer Network (NCCN) risk categories — low-, intermediate-, and high-risk are largely based on the Gleason score as determined by the microscopic appearance of cells and their organization. However, beneath the surface appearance...
    « Older Entries
    Prostate Cancer Free Foundation

    Prostate Cancer Free Foundation
    10016 Edmonds Way Ste C #153
    Edmonds, WA 98020

    Select Language:

    • Prostate Cancer
    • Risk Factors
    • Symptoms
    • The Prostate
    • Tests and Diagnosis
    • PSA
    • Gleason Score
    • Stages
    • Risk Groups
    • Patient Advice
    • Patient Worksheet
    • Diet & Lifestyle
    • Glossary & Terms
    • Commentary & News
    • Videos
    • Treatment Options
    • Comparing Treatments
      • Low
      • Intermediate
      • High
    • Side Effects
    • Successful Treatments
    • Get the Study
      Copyright 2017 Prostate Cancer Free Foundation | ProstateCancerFree.org was optimized for performance by WpFASTER